Miwon is excited to announce the development of a new antimicrobial tripeptide,
DermaPep™ M330, one of the shortest peptides that shows the powerful
antimicrobial efficacy. It is known that most atopic dermatitis (AD) patients show
much more colonization of Staphylococcus aureus than healthy subjects on the skin
and the toxins produced from S. aureus aggravate the symptom of AD.
DermaPep™ M330 is therefore developed to protect the skin of atopic dermatitis patients
from further microbial attacks.
In addition, comparison study to other currently known preservatives shows that
DermaPep™ M330, a broad spectrum antimicrobial peptide, can be a powerful
substitute where no toxic or problematic preservation systems are required.
For further information, please check it in product section.
|
